Target General Information
Target ID T37539 Target Info
Target Name B-cell receptor CD22 (CD22)
Synonyms T-cell surface antigen Leu-14; Siglec-2; Sialic acid-binding Ig-like lectin 2; SIGLEC2; Leu-14; BL-CAM; B-lymphocyte cell adhesion molecule
Target Type Successful Target
Gene Name CD22
Biochemical Class Immunoglobulin
UniProt ID
Targeted Antigens of CAR-T Cell Therapy
CAR T-Cell Therapy Drug(s) CAR-T cells targeting CD22 Drug Info Phase 2 Non-hodgkin lymphoma [1]
4SCAR19 and 4SCAR22 Drug Info Phase 1/2 B-cell lymphoma [2]
4SCAR19/22 T cells Drug Info Phase 1/2 leukaemia [3]
Anti-CD19/22-CAR vector-transduced T cells Drug Info Phase 1/2 Prolymphocytic leukaemia [4]
Anti-CD22 CAR-T cells Drug Info Phase 1/2 Lymphoma [5]
Anti-CD22-CAR-transduced T cells Drug Info Phase 1/2 Lymphoma [6]
AUTO3 Drug Info Phase 1/2 Diffuse large B-cell lymphoma [7], [8]
CAR-T cells targeting CD22 Drug Info Phase 1/2 Multiple myeloma [9]
CART-19/22 Drug Info Phase 1/2 leukaemia [10]
CD19 and CD22 CAR-T Cells Drug Info Phase 1/2 leukaemia [11]
CD19 and CD22 CAR-T Cells Drug Info Phase 1/2 Lymphoma [12]
CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells Drug Info Phase 1/2 Haematopoietic/lymphoid cancer [13]
CD22 CAR-T Drug Info Phase 1/2 B-cell lymphoma [14]
CD22-Targeted CAR-T cells Drug Info Phase 1/2 Lymphoma [15]
Anti-CD22 CAR-T cells Drug Info Phase 1 Lymphoma [16]
CART-22 cells Drug Info Phase 1 Acute lymphoblastic leukaemia [17]
CART22 cells Drug Info Phase 1 Acute lymphoblastic leukaemia [18]
CART22 cells expressing anti-CD22 scFv TCRz:41BB Drug Info Phase 1 Acute lymphoblastic leukaemia [19]
CART22-65s cells Drug Info Phase 1 Acute lymphoblastic leukaemia [20]
CART22-65s cells and huCART19 Cells Drug Info Phase 1 Acute lymphoblastic leukaemia [20]
CD19/CD22 CAR T cells Drug Info Phase 1 Acute lymphoblastic leukaemia [21]
CD19/CD22 CAR T-Cells Drug Info Phase 1 Non-hodgkin lymphoma [22]
CD19/CD22 Chimeric Antigen Receptor T Cells Drug Info Phase 1 Mediastinal large B-cell lymphoma [23]
CD22-CART Drug Info Phase 1 leukaemia [24]
CD22-specific CAR T-cells also expressing an EGFRt Drug Info Phase 1 leukaemia [25]
Donor-derived CD19/22 bispecific CAR-T cells Drug Info Phase 1 leukaemia [26]
Dual Specificity CD19 and CD22 CAR-T Cell Drug Info Phase 1 Lymphoma [27]
Patient-derived CD19- and CD22 specific CAR Drug Info Phase 1 Lymphoma [28]
Retroviral vector-transduced autologous T cells to express CD22-specific CARs Drug Info Phase 1 Mantle cell lymphoma [29]
References
REF 1 ClinicalTrials.gov (NCT03196830) CAR-T for R/R B-NHL
REF 2 ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
REF 3 ClinicalTrials.gov (NCT03098355) Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies
REF 4 ClinicalTrials.gov (NCT03185494) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22
REF 5 ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
REF 6 ClinicalTrials.gov (NCT03262298) Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies
REF 7 ClinicalTrials.gov (NCT03289455) CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell ALL
REF 8 ClinicalTrials.gov (NCT03287817) CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma
REF 9 ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
REF 10 ClinicalTrials.gov (NCT03614858) CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
REF 11 ClinicalTrials.gov (NCT03398967) A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma
REF 12 ClinicalTrials.gov (NCT03468153) Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma
REF 13 ClinicalTrials.gov (NCT02903810) Combination Transfer of CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells for B-cell Hematologic Malignancy
REF 14 ClinicalTrials.gov (NCT02794961) CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies
REF 15 ClinicalTrials.gov (NCT02935153) A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
REF 16 ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
REF 17 ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
REF 18 ClinicalTrials.gov (NCT02588456) Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia
REF 19 ClinicalTrials.gov (NCT02650414) CD22 Redirected Autologous T Cells for ALL
REF 20 ClinicalTrials.gov (NCT03620058) CART22 Alone or in Combination With huCART19 for ALL
REF 21 ClinicalTrials.gov (NCT03241940) CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Children or Young Adults With Recurrent or Refractory CD19 Positive B Acute Lymphoblastic Leukemia
REF 22 ClinicalTrials.gov (NCT03448393) CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
REF 23 ClinicalTrials.gov (NCT03233854) CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Patients With Recurrent or Refractory CD19 Positive Diffuse Large B-Cell Lymphoma or B Acute Lymphoblastic Leukemia
REF 24 ClinicalTrials.gov (NCT03407859) Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL
REF 25 ClinicalTrials.gov (NCT03244306) A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma
REF 26 ClinicalTrials.gov (NCT03463928) A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia
REF 27 ClinicalTrials.gov (NCT03593109) Safety and Efficacy Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in Relapsed or Refractory Lymphoma
REF 28 ClinicalTrials.gov (NCT03330691) A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia and Lymphoma
REF 29 ClinicalTrials.gov (NCT02721407) Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.